// App-Quantinova.ai

: Direct and Indirect Treatment Effect of Guselkumab on Anxiety and Depression in Patients With Psoriasis by Adjusting for Psoriasis Area and Severity Index (PASI) – A Mediation Analysis

Researchers

Presenter

  • April Armstrong

Principal Investigators

  • Peter Foley

  • Yan Liu

  • Ya-Wen Yang

  • Megan Miller

  • Rachel E. Teneralli

  • Anthony Bewley

  • Kenneth B. Gordon

  • Chenglong Han

Medical Centers

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

  • The University of Melbourne, St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute, Department of Medicine, Carlton, Australia

  • Janssen Global Services, LLC, Horsham/Malvern, PA, USA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Research and Development, LLC, Spring House, PA

  • Barts Health NHS Trust, London, United Kingdom

  • The Medical College of Wisconsin, Milwaukee, WI

Locations

  • Australia

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Central Nervous System (CNS)

  • Dermatology

Disease

  • Depression

  • Psoriasis

  • Anxiety

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved